10x Genomics (TXG) Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TXG shares.
View TXG analyst ratings or view top-rated stocks.

12 Wall Street research analysts have issued 12-month price targets for 10x Genomics' stock. Their TXG share price forecasts range from $25.00 to $68.00. On average, they expect the company's stock price to reach $54.85 in the next year. This suggests a possible upside of 0.5% from the stock's current price.
View analysts price targets for TXG or view top-rated stocks among Wall Street analysts.

10x Genomics' stock was trading at $36.44 at the start of the year. Since then, TXG shares have increased by 49.8% and is now trading at $54.60.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our TXG earnings forecast.

10x Genomics, Inc. (NASDAQ:TXG) released its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.06. The business had revenue of $134.29 million for the quarter, compared to analysts' expectations of $128.87 million. 10x Genomics had a negative net margin of 32.51% and a negative trailing twelve-month return on equity of 22.02%. 10x Genomics's quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.38) EPS.

ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ARK Innovation ETF (ARKK), Invesco DWA Healthcare Momentum ETF (PTH), Principal Healthcare Innovators ETF (BTEC), First Trust Multi-Manager Large Growth ETF (MMLG) and ERShares Entrepreneurs ETF (ENTR).

10x Genomics updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $590.00 million-$610.00 million, compared to the consensus revenue estimate of $593.20 million.

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

(TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

10x Genomics trades on the NASDAQ under the ticker symbol "TXG."

10x Genomics' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (7.59%), BlackRock Inc. (4.54%), FMR LLC (3.79%), ARK Investment Management LLC (3.60%), Sands Capital Management LLC (3.24%) and Brown Capital Management LLC (2.67%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends.

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TXG stock can currently be purchased for approximately $54.60.

10x Genomics (NASDAQ:TXG) has a market capitalization of $6.34 billion and generates $516.41 million in revenue each year. The company earns $-166,000,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

The company employs 1,239 workers across the globe.

10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The official website for the company is www.10xgenomics.com. The company can be reached via phone at 925-401-7300 or via email at investors@10xgenomics.com.